Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer

Drugs and Aging

Volumn 24, Issue 2, 2007, Pages 169-171

  Wellington, Keri ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; PLACEBO;

ADJUVANT THERAPY; ADVANCED CANCER; ANALYTIC METHOD; CASTRATION; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; GYNECOMASTIA; HEART FAILURE; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; LIVER FUNCTION TEST; MASTALGIA; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SURGICAL TECHNIQUE;

ANILIDES; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; NITRILES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE; TOSYL COMPOUNDS;

EID: 33847258452     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724020-00008     Document Type: Review

References (19)

1. Klotz L, Schellhammer P. Combined androgen blockade: the case for bicalutamide. Clin Prostate Cancer 2005 Mar; 3 (4): 215-9
2. Masiello D, Cheng S, Bubley GJ, et al. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002 Jul 19; 277 (29): 26321-6
3. Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 2004; 93 (9): 1177-82
4. Verhelst J, Denis L, Van Vliet P, et al. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 1994 Oct; 41: 525-30
5. Denis L, Mahler C. Pharmacodynamics and pharmacokinetics reof bicalutamide: defining an active dosing regimen. Urology 1996 Jan; 47 Suppl. 1A: 26-8
6. Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005 Feb 1; 23 (4): 808-15
7. McLeod DG, Iversen P, See WA, et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97 (2): 247-54
8. Iversen P, Tyrrell CJ, Kaisary AM, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000 Nov; 164: 1579-82
9. Sieber PR, Keiller DL, Kahnoski RJ, et al. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004 Jun; 171 (6 Pt 1): 2272-6
10. Smith MR, Goode M, Zietman AL, et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004 Jul 1; 22 (13): 2546-53
11. Cockshott ID. Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet 2004; 43 (13): 855-78
12. See WA, McLeod D, Iversen P, et al. The bicalutamide Early Prostate Cancer Program: demography. Urol Oncol 2001; 6: 43-7
13. See WA, Wirth MP, McLeod DG, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer program. J Urol 2002 Aug; 168: 429-35
14. Wirth MP, See WA, McLeod DG, et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer program at median followup of 5.4 years. J Urol 2004; 172 (5 Pt 1): 1865-70
15. Iversen P, Johansson J-E, Lodding P, et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004 Nov; 172 (5 Pt 1): 1871-6
16. Iversen P, Johansson JE, Lodding P, et al. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median followup period of 7.1 years. Scand J Urol Nephrol 2006; 40 (6): 441-52
17. Wirth M, Tyrrell C, Delaere K, et al. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up. Prostate Cancer Prostatic Dis 2006 Nov 14, Epub ahead of print
18. McLeod DG, See WA, Klimberg I, et al. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J Urol 2006 Jul; 176 (1): 75-80
19. Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998 Mar; 51: 389-96